| 1 |
34668025 | Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. | 2022 Feb |
3 |
| 2 |
35152405 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. | 2022 May |
2 |
| 3 |
35335877 | The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. | 2022 Feb 24 |
5 |
| 4 |
35399656 | Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers. | 2022 |
1 |
| 5 |
33742787 | Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters. | 2021 Jul |
1 |
| 6 |
34162690 | Comparative Hepatic and Intestinal Efflux Transport of Statins. | 2021 Sep |
3 |
| 7 |
34164937 | Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. | 2021 Sep |
5 |
| 8 |
34603040 | Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach. | 2021 |
2 |
| 9 |
31378968 | Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat. | 2020 Jan |
1 |
| 10 |
32361904 | Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. | 2020 Jul |
1 |
| 11 |
32453913 | Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. | 2020 Nov |
5 |
| 12 |
32592633 | Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin. | 2020 Nov |
1 |
| 13 |
33037044 | Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models. | 2020 Dec |
1 |
| 14 |
29950617 | Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. | 2019 Apr |
1 |
| 15 |
30921829 | Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation. | 2019 Apr |
1 |
| 16 |
31102467 | Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. | 2019 Nov |
1 |
| 17 |
31571146 | Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. | 2019 Dec |
1 |
| 18 |
31857620 | Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. | 2019 Dec 19 |
6 |
| 19 |
28653144 | Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. | 2018 Apr |
1 |
| 20 |
29440178 | Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. | 2018 May |
3 |
| 21 |
29724614 | Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. | 2018 Jun |
1 |
| 22 |
30083819 | Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse. | 2018 Sep |
2 |
| 23 |
27737931 | Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. | 2017 Jan |
3 |
| 24 |
28385543 | Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. | 2017 Sep |
3 |
| 25 |
26700956 | Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. | 2016 Mar |
6 |
| 26 |
27146814 | No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. | 2016 Aug |
3 |
| 27 |
27557342 | Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. | 2016 Nov |
3 |
| 28 |
27651239 | Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. | 2016 Dec |
4 |
| 29 |
25630984 | Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. | 2015 Mar |
1 |
| 30 |
25673568 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? | 2015 Mar |
4 |
| 31 |
25740267 | Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. | 2015 May |
1 |
| 32 |
26081159 | Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote. | 2015 Sep |
5 |
| 33 |
23881596 | A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. | 2014 Jan |
3 |
| 34 |
24440960 | Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. | 2014 Apr |
2 |
| 35 |
23289909 | Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. | 2013 Mar |
1 |
| 36 |
23469685 | ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. | 2013 Feb |
2 |
| 37 |
23930675 | Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. | 2013 Aug |
4 |
| 38 |
22081364 | Rosuvastatin blocks hERG current and prolongs cardiac repolarization. | 2012 Feb |
1 |
| 39 |
22331829 | Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. | 2012 Apr 1 |
1 |
| 40 |
23118302 | Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. | 2012 Dec |
1 |
| 41 |
21091277 | The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. | 2011 Jan |
1 |
| 42 |
21447733 | Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. | 2011 Jul |
1 |
| 43 |
20130569 | ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. | 2010 May |
3 |
| 44 |
20207952 | Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. | 2010 Jun |
3 |
| 45 |
19474787 | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | 2009 Aug |
2 |
| 46 |
18612079 | Human proximal tubular epithelium actively secretes but does not retain rosuvastatin. | 2008 Oct |
1 |
| 47 |
18617601 | Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. | 2008 Oct |
4 |
| 48 |
16415124 | ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. | 2006 May |
6 |
| 49 |
16784736 | Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. | 2006 Nov |
5 |